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Abstract
Heme is required for cell respiration and survival. Nevertheless, its intracellular levels need to be finely regulated to
avoid heme excess, which may catalyze the production of reactive oxygen species (ROS) and promote cell death. Here,
we show that alteration of heme homeostasis in endothelial cells due to the loss of the heme exporter FLVCR1a, results
in impaired angiogenesis. In vitro, FLVCR1a silencing in endothelial cells causes defective tubulogenesis and poor
viability due to intracellular heme accumulation. Consistently, endothelial-specific Flvcr1a knockout mice show
aberrant angiogenesis responsible for hemorrhages and embryonic lethality. Importantly, we demonstrate that impaired
heme export leads to endothelial cell death by paraptosis and provide evidence that endoplasmic reticulum (ER) stress
precedes heme-induced paraptosis. These findings highlight a crucial role for the cytosolic heme pool in the control of
endothelial cell survival and in the regulation of the angiogenic process. Interfering with endothelial heme export
represents a valuable model for a deeper understanding of the molecular mechanisms underlying heme-triggered
paraptosis and, in the future, might provide a novel tool for the modulation of angiogenesis in pathophysiologic
conditions.
Introduction
Blood vessels originate from endothelial precursors
(angioblasts), which give rise to a primitive vascular
labyrinth of small capillaries, a process known as vascu-
logenesis [1]. During subsequent angiogenesis, the vascular
plexus progressively expands through vessel sprouting [1].
The sprouting process is based on endothelial cell (EC)
migration toward chemotactic and angiogenic stimuli,
proliferation and tube formation. Afterward, a highly
organized network of larger vessels ramifying into smaller
ones, emerges. A functional circulatory system is essential
to guarantee oxygen and nutrients delivery to distant
organs [2]. Consistently, angiogenesis is crucial for organ
growth in the developing embryo and repair of wounded
tissues in the adult [1]. Many molecular players are
involved in the formation and remodeling of blood vessels,
including growth factors, integrins, chemokines, junctional
molecules and oxygen sensors. Interestingly, metabolic
demands are also thought to modulate angiogenesis [3].
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Intrinsic, as well as extrinsic factors involved in the reg-
ulation of angiogenesis, show a dual role, by both stimu-
lating vessel growth and inhibiting EC death. Indeed,
excessive cell death might interfere with angiogenesis and
actively lead to vessel regression [4]. Stimuli that cause
endothelial injury or death include environmental stressors
such as oxidative stress and nutrient deprivation, endo-
plasmic reticulum (ER) stress and metabolic stress [5, 6].
Here, we provide evidence that heme homeostasis in ECs
controls the angiogenic process. In particular, we show that
the expression of the heme exporter Feline leukemia virus
subgroup C receptor 1a (FLVCR1a) on ECs is essential for
proper angiogenesis. FLVCR1 is a widely conserved heme
export protein, which exists as two isoforms, FLVCR1a
and FLVCR1b, located at the plasma and mitochondrial
membrane, respectively [7]. Heme, a complex of iron with
protoporphyrin IX, is required for many biological pro-
cesses, including oxygen transport, cell respiration and
drug metabolism but has also cytotoxic properties as a pro-
oxidant molecule [8]. Therefore, intracellular heme levels
are strictly regulated through the biosynthesis, the incor-
poration in hemoproteins, the catabolism and the export
[9]. Heme export through FLVCR1a has proved funda-
mental in preventing intracellular heme overload and heme-
induced oxidative stress in many cellular systems, includ-
ing HeLa, Caco2, primary hepatocytes and macrophages
[7, 10–12]. Furthermore, FLVCR1a loss in mice causes
embryonic lethality [7], whereas intestinal-specific deletion
impairs normal proliferation in enterocytes and FLVCR1a
depletion in a mouse model of ulcerative colitis is asso-
ciated with reduced animal survival [12]. Consistently,
FLVCR1a silencing affects cell viability in K562 cells [13]
and induces programmed cell death (PCD) in neuro-
blastoma cells [14]. These data suggest that FLVCR1a
deficiency may increase the susceptibility to PCD. Here,
we show that FLVCR1a loss in ECs leads to an expansion
of the intracellular heme pool and promotes cell death by
paraptosis, a specific type of PCD. Paraptosis of Flvcr1a
null ECs in mouse embryo prevents the formation of a
functional microvascular network, thus leading to extensive
hemorrhages and embryonic lethality.
Results
Silencing of FLVCR1a in human ECs results in
increased heme levels and reduced viability
FLVCR1a has been reported to act as a heme exporter in
hepatocytes [10], enterocytes [12] and erythroid cells [13].
Here, we tested whether FLVCR1a exerts a similar function
in ECs. To address this point, we downmodulated
FLVCR1a in two different types of human primary ECs: the
human microvascular ECs (HMECs) and the human
umbilical vein ECs (HUVECs), which derive from micro-
and macro-vasculature, respectively. To downmodulate
FLVCR1a, ECs have been infected with a lentiviral vector
carrying the specific short hairpin RNA (shRNA) for
FLVCR1a or a “scramble” shRNA as control. FLVCR1a
mRNA levels were significantly reduced to about 40% in
both HMECs (Fig. 1a) and HUVECs (Fig. 1c). Conversely,
the FLVCR1b isoform was not affected (Figs. 1b, d). To
study the effects of FLVCR1a loss on heme metabolism, the
expression of heme-regulated genes was assessed in
silenced human primary ECs. Interestingly, we found
reduced levels of the δ-aminolevulinic acid synthase-1
(ALAS-1), the first and rate-limiting enzyme involved in
heme biosynthetic pathway, in FLVCR1a-downregulated
HMECs and HUVECs compared with scramble cells
(Figs. 1e, g). The expression of heme oxygenase-1 (HO1),
the enzyme mainly responsible for heme catabolism, was
not altered in HMECs and slightly but not significantly
increased in HUVECs after FLVCR1a silencing (Figs. 1f,
h). These data suggest that the first compensatory response
to the lack of heme export in ECs is the decrease of
endogenous heme biosynthesis. Next, we directly measured
the intracellular heme content in basal HMECs and we
found a higher amount of heme after FLVCR1a silencing
compared with scramble cells (Fig. 1i). In HUVECs, we did
not find any difference in heme levels after FLVCR1a
silencing (Fig. 1k). This is likely due to the more efficient
downmodulation of ALAS1 and the slight increase in HO1
in HUVECs compared with HMECs, which might better
compensate for the lack of heme export in this cell line.
However, FLVCR1a-downregulated HUVECs showed
increased intracellular heme levels compared with control
cells, upon treatment with the heme precursor δ-
Aminolevulinic acid (ALA) (Fig. 1k). Notably, the
increased intracellular heme content was associated to a
higher production of reactive oxygen species (ROS) in
HMECs under resting conditions and in HUVECs following
ALA treatment (Figs. 1j, l), as previously reported in other
cell types undergoing intracellular heme accumulation [10,
12, 15]. Taken together, these data show that FLVCR1a-
downregulated ECs accumulate de novo synthetized heme,
which in turn gives rise to high ROS production. To
investigate the effects of heme overload on ECs viability,
we performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay and flow cytometry ana-
lysis after Annexin V staining. Interestingly, FLVCR1a-
silenced cells were less viable (Figs. 1m, o) and a higher
percentage of Annexin V-positive cells was found in
FLVCR1a-downregulated HMECs and HUVECs compared
with scramble cells (Figs. 1n, p).
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Fig. 1 Lack of FLVCR1a results in increased heme levels and reduced
viability in endothelial cells. a-h qRT-PCR analysis of FLVCR1a a, c,
FLVCR1b b, d, ALAS1 e, g and HO1 f, h in HMECs a, b, e, f or
HUVECs c, d, g, h in which the expression of FLVCR1a was
downregulated using a specific shRNA 1a. Transcript abundance,
normalized to 18s mRNA expression, is expressed as a fold increase
over a calibrator sample. Data represent mean± SEM, n= 5; *p<
0.05, **p< 0.01, ***p< 0.001. i, k Heme content in HMECs i or
HUVECs k in which the expression of FLVCR1a was downregulated
using a specific shRNA. Intracellular heme levels in HUVECs cultured
in basal condition or treated with δ-aminolevulinic acid (ALA) 5 mM
for 2–4 h, are shown in k. Values are expressed as pmol heme/mg
protein. Data represent mean ± SEM, n= 10; *p< 0.05, **p< 0.01,
***p< 0.001, ****p< 0.0001. j, l ROS amount measured by detec-
tion of H2DCFDA fluorescence in HMECs j or HUVECs l with or
without FLVCR1a in basal condition or after treatment with ALA
5mM for 15 h. Values are expressed as FIU/mg protein. Data repre-
sent mean± SEM, n= 4; *p< 0.05. m, o Cell viability assessed
through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay of HMECs m or HUVECs o in which the expression of
FLVCR1a was downregulated using a specific shRNA. Values are
expressed as percentage increase at 24, 48 h compared with T0 (time
zero). Data represent mean ± SEM, n= 8 (HMECs), n= 3 (HUVECs);
***p< 0.001, ****p< 0.0001. n, p Flow cytometry assay performed
on HMECs n or HUVECs p with or without FLVCR1a, after incu-
bation with Annexin V-FITC antibody. Values are expressed as per-
centage of Annexin V high/PI low cells. Data represent mean± SEM,
n= 3; *p< 0.05. ALAS1 δ-aminolevulinate synthase-1; HO1 heme
oxygenase-1; RQ relative quantification; qRT-PCR quantitative real-
time PCR; ROS reactive oxygen species; shRNA short hairpin RNA;
ALA δ-aminolevulinic acid; PI propidium iodide
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Fig. 2 Endothelial loss of FLVCR1a results in embryonic lethality. a
Schematic representation of the knockout strategy in mice. Briefly, we
named “floxed allele” the allele in which the first exon of Flvcr1 gene
was flanked by loxP sites, recognizable by the Cre transgene. The
excision of exon 1 results in a null allele preventing the production of
FLVCR1a protein. b Representative PCR products from yolk sac
DNA analysis of E13.5 embryos. Specific primers allowed distin-
guishing the wt (242 bp), floxed (280 bp) and null allele (320 bp) of
Flvcr1a. c, d qRT-PCR analysis showing Flvcr1a mRNA levels in
E13.5 whole embryo c and yolk sac d. Data represent mean± SEM;
*p< 0.05, **p< 0.01. e Phenotype of E11.5 control and Flvcr1a eKO
embryos. f E13.5 embryos enfolded in their yolk sacs. At E13.5, major
yolk sac vessels in Tie2-Cre conditional mutant embryos are clearly
visible and hemorrhagic spots were often observed within the yolk sac
(white arrows). g Representative picture of E13.5 control and Flvcr1a
eKO embryos with undeveloped limbs and intraembryonic hemor-
rhages (white arrows). h, i Representative pictures of E14.5 h and
E16.5 i embryos. At E16.5 endothelial Flvcr1a knockout, embryos
begin to be re-absorbed by the endometrium. White arrows indicate
hemorrhages. j X-ray computer micro-tomography analysis on E13.5
embryos showing the internal organ morphology. k Sagittal sections
from E13.5 embryos stained with hematoxylin and eosin to look at the
cellular morphology in tissues. RQ relative quantification; eKO,
Flvcr1a endothelial knockout; E embryonic stage
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These data demonstrate that ECs are highly sensitive to
the absence of the cell surface heme exporter, as the loss of
FLVCR1a leads to intracellular heme accumulation, oxi-
dative stress and reduced cell viability.
Endothelial deletion of Flvcr1a leads to embryonic
lethality and extensive hemorrhages in vivo
To study the role of FLVCR1a in ECs in vivo, we gen-
erated an endothelial-specific knockout (eKO) mouse
model for FLVCR1a (Figs. 2a-d). To this end, we crossed
FLVCR1a floxed mice with Tie2-Cre mice, expressing the
Cre recombinase under the control of the Tie2 promoter,
which is mainly active in the endothelial and erythroid
compartments. Importantly, we did not recover any viable
Flvcr1a eKO within the offspring (Table 1), thus indicat-
ing that disruption of Flvcr1a gene in ECs results in
embryonic lethality. Flvcr1a eKO embryos were found at
the expected Mendelian ratio from embryonic stage E11.5
to embryonic stage E14.5 (Table 1). At 11.5 days of
embryonic development, Flvcr1a eKO embryos appeared
normal (Fig. 2e). Starting from E12.5, massive intraem-
bryonic bleeding was visible in the distal regions of the
body, particularly the developing limbs or the tail, and in
the yolk sac (Figs. 2f-h). In Flvcr1a eKO limbs, the
hemorrhages were often associated to edema and skeletal
malformation, as suggested by impaired digits formation
(Figs. 2g, h). At E14.5 Flvcr1a eKO embryos appeared
heavily damaged (Fig. 2h), whereas at E16.5 viable
Flvcr1a eKO embryos were no longer found (Fig. 2i). This
phenotype showed complete penetrance indicating that
FLVCR1a loss in ECs leads to severe bleeding in vivo and
embryonic death between E14.5 and E15.5. To better
investigate the organogenesis and overall morphology in
Flvcr1a eKO embryos, X-ray computed micro-computed
tomography (micro-CT) was performed on E13.5 embryos
(Fig. 2j). The analysis of embryonic internal organs did not
reveal the presence of evident malformations in Flvcr1a
eKO embryos compared with controls, except for the fetal
liver that was smaller in Flvcr1a eKO embryos due to the
Cre activity in erythroid precursors [13] (Supplementary
Figure S1). Consistently, the histological analysis per-
formed on E12.5 Flvcr1a eKO showed no altered cell
morphology in major organs (Fig. 2k).
Collectively, our results indicate that FLVCR1a loss in
ECs impairs vascular development by leading to severe
hemorrhages and late intrauterine fetal death.
Loss of FLVCR1a in ECs disrupts microvessel
architecture
To further investigate the cause of hemorrhages, we ana-
lyzed the vasculature of Flvcr1a eKO embryos at E11.5
when hemorrhages were not detectable, by performing
whole-mount staining for PECAM-1 (CD31), a pan-EC
marker. At the level of developing limbs, which are the sites
where hemorrhages would appear earlier, the structure of
the vascular network was severely impaired in E11.5
Flvcr1a eKO embryos compared with controls (Fig. 3a). In
control embryos, a well-defined network of capillaries was
properly organized throughout the limb bud. Conversely, in
Flvcr1a eKO mutants, microvessel architecture was com-
promised and large areas completely devoid of vessels were
observed in both the forelimbs and the hindlimbs (Fig. 3a).
Notably, when we looked at the vascular network in other
regions of E11.5 Flvcr1a eKO embryo’s body, as the yolk
sac and the head, vessels appeared generally intact (Sup-
plementary Figure S2). As the limbs’ capillaries are mainly
composed of microvascular cells, we used HMECs to study
the ability of FLVCR1a-silenced human microvascular cells
to generate tubule-like structures in vitro. Interestingly,
silenced cells showed a reduced ability to form a complex
capillary network compared with scramble cells (Fig. 3b).
These results highlight a key role for FLVCR1a in the
formation of a properly patterned capillary network, which
is essential for the development of a functional circulatory
system.
Loss of FLVCR1a in ECs causes paraptotic cell death
In order to understand why FLVCR1a-deficient ECs fail to
form a proper capillary network, we performed electron
microscopy analysis on forelimb transverse sections from
both Flvcr1a eKO and control E11.5 embryos (Fig. 4).
Flvcr1a null ECs were characterized by the presence of
several intracellular vacuoles of different sizes and shapes
(Figs. 4a, b, d, e). The vacuoles often originated from an
enlargement of the ER and mitochondria (Figs. 4c, f).
Table 1 Loss of FLVCR1a in
endothelial cells leads to
embryonic death
Embryonic stage N Flvcr1aflox/+ Flvcr1aflox/+ Tie2Cre Flvcr1aflox/flox Flvcr1aflox/flox Tie2cre
11.5–12.5 57 10 (17.5%) 14 (24.5%) 13 (22.8%) 20 (35%)
13.5 190 32 (16.8%) 56 (29.5%) 56 (29.5%) 46 (24,2%)
14.5 28 8 (28.6%) 7 (25%) 6 (21.4%) 7 (25%)
Newborns 46 13 (28.2%) 17 (36.9%) 16 (34.7%) 0 (0%)
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Fig. 3 Flvcr1a endothelial knockout embryos show impaired vascular
integrity. a Whole-mount staining with CD31/Pecam-1 antibody
showing the embryonic vasculature in E11.5 embryos. Enlarged pic-
tures of both the forelimb (left) and the hindlimb (right) are reported. b
Matrigel-based tube formation assay of HMECs in which the
expression of FLVCR1a was downregulated using a specific shRNA.
The histograms of the number of nodes, junctions, segments and
isolated segments are shown. The total segments length is also
reported. Data represent mean ± SEM, n= 19; *p< 0.05. eKO
Flvcr1a endothelial knockout; scr cells infected with a “scramble”
shRNA; 1a, cells infected with a shRNA specific for FLVCR1a
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Intracellular vacuoles can reach extended size, sometimes
affecting the entire cytoplasmt (Figs. 4g-i). Interestingly,
cytoplasmic vacuolation is the main feature of paraptosis, a
specific type of PCD characterized by ER and mitochondria
swelling and lack of apoptotic or autophagic morphology
[16]. Consistently, the defining morphological hallmarks of
apoptosis such as chromatin condensation, nuclear frag-
mentation and apoptotic body formation, were not observed
in Flvcr1a null ECs (Fig. 5a). Moreover, the intracellular
vacuoles observed in ECs without FLVCR1a did not
contain fragments of cellular organelles and in most cases
were defined by single membranes, leading us to exclude an
autophagic mechanism (Fig. 5b). To confirm that Flvcr1a
null ECs undergo paraptosis, we analyzed CD31+ cells
isolated from Flvcr1a eKO embryos (Figs. 5c-e, Supple-
mentary Figure S3) for biochemical markers of this type of
cell death, that is, translocation of phosphatidylserine to the
cell surface, no caspase activation and lack of expression of
autophagic markers [16–18]. As shown in Figs. 5f, g, we
found a higher percentage of Annexin V-positive cells in
Fig. 4 Endothelial cells without FLVCR1a show paraptotic cell death
morphological features. a-i Electron microscopy analysis performed
on transverse section from E11.5 embryonic forelimbs. Two capillaries
from a control a, b and an eKO d, e embryo are shown. Flvcr1a null
ECs display extensive cytoplasmic vacuolation d, e and an altered
swollen morphology of ER and mitochondria f compared with controls
c. In g, a small limb capillary made of two Flvcr1a null ECs is shown.
The presence of huge intracellular vacuoles and heavily damaged
mitochondria without cristae (black arrowheads) is clearly visible in
the enlargements h, i. eKO Flvcr1a endothelial knockout; BC blood
cell; EC endothelial cell; IEJ inter endothelial junction; V vacuole; M
mitochondrion; N nucleus; ER endoplasmic reticulum
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Fig. 5 FLVCR1a null endothelial cells accumulate heme and show
reduced viability in vivo. a Electron micrographs showing the nuclear
morphology of a control (left) and an Flvcr1a null EC (right). The
main apoptotic features as chromatin condensation and nuclear frag-
mentation are not observed in Flvcr1a null ECs. b Electron micro-
graphs showing the single-membrane vacuoles (black arrowheads) in
Flvcr1a null ECs from E11.5 forelimb transverse sections. c Optical
imaging on CD31+ cells isolated from E13.5 control and eKO
embryos. Black arrows indicate intracellular vacuoles. d, e qRT-PCR
analysis of Flvcr1a d and Flvcr1b e in CD31-positive and -negative
cell fractions from E13.5 embryos. Values represent mean± SEM; n
= 5; ***p< 0.001. f, g Flow cytometer analysis of CD31+ cells from
E11.5 f and E14.5 g embryos after staining with Annexin V. The
percentage of Annexin V/CD31 double-positive cells is reported. *p<
0.05, **p< 0.01. h Western blot analysis of full-length (35 kDa) and
cleaved (17–19 kDa) caspase-3. The active form of caspase-3 was not
detected in CD31+ cells from E13.5 eKO embryos. As positive
control HUVEC cells treated for 3 h with 5 μM STS were used. i
Western blot analysis of the autophagy protein LC3. The ratio between
LC3-II (14 kDa) and LC3-I (17 kDa) does not change in CD31+
Flvcr1a null ECs. j Quantification of normalized LC3-II/I ratio. Values
are expressed as fold increase. k Intracellular heme levels in CD31+
cells isolated from E13.5 embryos. Values for each sample are
expressed as the ratio between the fluorescence of CD31+ cells and
the total fluorescence (CD31+/-). *p< 0.05. l qRT-PCR analysis of
Ho-1 in CD31+ cells from E13.5 control and eKO embryos. Values
represent mean± SEM; n= 5. eKO, Flvcr1a endothelial knockout; EC
endothelial cell; N nucleus; STS Staurosporine
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Flvcr1a null ECs at both E11.5 and E14.5. Moreover,
Flvcr1a null ECs did not express activated caspase-3
(Fig. 5h) and did not show abnormal expression of the
autophagic marker LC3B (Figs. 5i, j). Importantly, these
morphological and biochemical features were associated to
heme overload (Fig. 5k) and normal expression of HO1
(Fig. 5l) suggesting that developing ECs are fully dependent
on heme export for detoxifying heme excess. Taken toge-
ther, these data demonstrate that loss of FLVCR1a in ECs
leads to heme accumulation which triggers paraptotic cell
death.
To further characterize the mechanism of cell death
promoted by endogenously synthetized heme overload in
ECs, we performed electron microscopy on FLVCR1a-
silenced HMECs both under resting conditions and upon
treatment with ALA to stimulate heme synthesis. A proper
morphology and organization of the ER and mitochondria
was observed in control cells (Fig. 6a). Conversely, the ER
structure in FLVCR1a-silenced HMECs appeared
disorganized and some swollen ER cisternae were observed
(Fig. 6b). Moreover, a high number of small vacuoles
partially containing electron-dense dots were found
throughout the cytosol of FLVCR1a-silenced HMECs
(Fig. 6b). Importantly, damaged mitochondria characterized
by a swollen morphology were also observed in HMECs in
the absence of FLVCR1a (Fig. 6b). Upon ALA treatment,
the same morphological alterations appeared also in control
cells, which showed a high number of small vacuoles,
swollen mitochondria and disorganized ER structure
(Fig. 6c). The phenotype of FLVCR1a-silenced HMECs
was strongly exacerbated by ALA treatment and huge
vacuoles and heavily damaged swollen mitochondria were
observed in the cytoplasm (Fig. 6d). Importantly, these
morphological features well resemble paraptotic cell death,
similarly to the above described embryonic Flvcr1a null
ECs. As paraptosis, as well as other PCDs, requires protein
synthesis, we studied the effects of the protein synthesis
inhibitor cycloheximide (CHX) on heme-induced
Fig. 6 Intracellular heme accumulation induces cytoplasmic vacuola-
tion in human primary endothelial cells. a-f Electron microscopy
analysis performed on control a, c, e and FLVCR1a-silenced b, d, f
HMECs. a Control HMECs displayed a well-organized ER and normal
mitochondria. b FLVCR1a-deficient HMECs showed some swollen
ER cisternae (black arrows) and many vacuoles partially containing
electron-dense dots (white arrowheads). Some damaged mitochondria
(*) were also observed. Interestingly, electron-dense deposits (black
arrowheads) were found in the cytosol of some FLVCR1a-deficient
HMECs. c Control HMECs treated with ALA 5mM for 16 h. ALA
treatment induced the same morphological changes observed in the
absence of FLVCR1a. Intracellular vacuoles (white arrowheads) and
swollen mitochondria (*), are shown. d FLVCR1a-silenced HMECs
treated with ALA displayed huge intracellular vacuoles (V) and
heavily damaged swollen mitochondria (*), indicating a mechanism of
paraptotic cell death. e, f HMECs co-treated with ALA and CHX (5
μg/ml) for 16 h, are shown. The inhibition of protein synthesis by
CHX strongly reduced the number and size of intracellular vacuoles.
Electron-dense dots in FLVCR1a-silenced cells f are indicated by
black arrowhead. ER endoplasmic reticulum; G Golgi apparatus; M
mitochondrion; N nucleus; V vacuole; CHX Cycloheximide; ALA
Aminolevulinic acid
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paraptosis. To this aim, we co-treated control and
FLVCR1a-deficient HMECs with ALA (5 mM) and CHX
(5 μg/ml). Notably, the number and size of intracellular
vacuoles was strongly reduced by CHX, indicating that
protein synthesis is required for this process (Figs. 6e, f).
Taken together, these data indicate that heme accumulation
in human ECs induces a program of death with the
morphological features typically observed in paraptotic
cells.
Elevated intracellular ROS have been reported in several
models of paraptosis [19, 20]. As heme is known to pro-
mote the formation of ROS, as reported in FLVCR1a-
silenced human ECs (Figs. 1j, l), we studied their possible
involvement in heme-induced paraptosis. To do this, we
directly measured ROS production in ECs isolated from
control and Flvcr1a eKO embryos. As shown in Supple-
mentary Figure S4, we found no differences in generic ROS
as well as in mitochondrial superoxide production between
Fig. 7 Heme accumulation in ECs induces ER stress. a-c qRT-PCR
analysis of Perk (protein kinase R (PKR)-like endoplasmic reticulum
kinase) a, Grp78/Bip (binding immunoglobulin protein) b and Grp94 c
in CD31+ cells isolated from E13.5 Flvcr1a eKO embryos. Data
represent mean± SEM, n= 5; *p< 0.05, ***p< 0.001. d Electron
micrographs from limb transverse section of E13.5 Flvcr1a eKO
embryo showing the swollen morphology of endoplasmic reticulum
(black arrowheads). e-g qRT-PCR analysis of PERK e, GRP78/BIP f
and GRP94 g in FLVCR1a-silenced HMECs. Data represent mean±
SEM, n= 5; *p< 0.05, **p< 0.01. hWestern blot analysis of GRP78/
BIP protein expression in HMECs treated with ALA 5mM for the
indicated times. eKO Flvcr1a endothelial knockout; EC endothelial
cell; M mitochondrion
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control and Flvcr1a null CD31+ cells (Supplementary
Figures S4A-B). Moreover, the expression levels of super-
oxide dismutase 1 (Sod1) in CD31+ cells did not change
between Flvcr1a eKO and controls (Supplementary Fig-
ure S4C). Although we cannot exclude that a mild pro-
duction of ROS can occur, these data suggest that ROS are
rather a contributory cause than a driving force in the
induction of heme-triggered endothelial paraptosis in vivo.
As proteasome dysfunction and accumulation of unfol-
ded proteins have been described in several paraptotic cells
[19, 21, 22], we investigate the possible involvement of ER
stress in heme-induced endothelial paraptosis. To this aim,
we evaluated the expression of main ER stress markers in
ECs without FLVCR1a. Interestingly, we found a sig-
nificant induction of PERK, GRP78/BIP and GRP94 tran-
scripts in Flvcr1a null embryonic ECs, as well as in human
ECs silenced for FLVCR1a (Figs. 7a-c, e-g). Another evi-
dence of ER stress derived from the electron micrographs of
Flvcr1a null ECs, widely characterized by the presence of
swollen ER cisternae (Fig. 7d). Finally, a time-course
experiment with the heme precursor ALA on human ECs
correlated de novo synthetized heme accumulation with
increasing expression of GRP78/BIP protein (Figs. 7h, i).
These data strongly indicate that heme-induced paraptosis
might be preceded by induction of ER stress.
Discussion
In the present study, we show that heme accumulation in
ECs due to heme export failure, triggers paraptotic cell
death responsible for aberrant angiogenesis (Fig. 8). These
findings might have important implications for physiologi-
cal, as well as pathological angiogenesis.
Heme toxicity on ECs has been widely studied in the
context of hemolytic diseases. During hemolysis, hemo-
globin derived from lysed erythrocytes, releases free heme
that accumulates in plasma and becomes a major source of
ROS [11, 23]. The endothelium is the first tissue facing the
heme-related oxidative insult due to intravascular hemo-
lysis. The exposure of the vessel wall to heme leads to ECs
activation, which involves increased expression of adhesion
molecules, leukocytes recruitment and cytokines production
[23, 24]. In this context, HO1 induction represents a valu-
able mechanism for counteracting heme toxicity [25].
Consistently, several articles reported the therapeutic effects
of HO1 overexpression in the vascular system [26, 27].
Here, we show that ECs are also highly sensitive to the
accumulation of heme derived by intracellular metabolism.
Indeed, heme overload in FLVCR1a-deficient ECs is asso-
ciated with poor cell viability both in vitro and in vivo.
Moreover, in Flvcr1a-silenced cells heme overload further
increases upon the stimulation of heme biosynthesis.
Interestingly, in Flvcr1a-deficient ECs, expanded intracel-
lular heme pool triggers a specific compensatory response
that is mainly mediated by the inhibition of heme bio-
synthesis, rather than by the induction of heme catabolism.
Thus, heme catabolism (HO1) and export (FLVCR1a) are
involved in the management of heme excess derived from
extracellular or intracellular sources, respectively. Collec-
tively, these data suggest the existence of distinct heme
pools on specific cell compartments, likely accessible to
different mechanisms of heme detoxification. This conclu-
sion is supported by data obtained in other cell types and in
Fig. 8 Schematic representation
of FLVCR1a function in
endothelial cells.. Graphic
representation of wild-type a
and FLVCR1a null b endothelial
cells. FLVCR1a exports the
excess of heme derived from
heme biosynthesis, thus
contributing to maintain heme
homeostasis. The loss of
FLVCR1a leads to cytosolic
heme accumulation and triggers
paraptotic cell death
characterized by extensive
cytoplasmic vacuolation,
swollen morphology of
endoplasmic reticulum and large
mitochondria without cristae.
The effects of FLVCR1a loss in
ECs in vivo cause deficient
angiogenesis, hemorrhages and
embryonic lethality. M
mitochondrion; ER endoplasmic
reticulum; V vacuoles; N
nucleus
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liver- and intestine-specific Flvcr1a null mice, where Ho1
induction cannot reduce heme overload caused by
FLVCR1a loss [10, 12].
In vivo, heme overload in Flvcr1a null ECs results in
increased cell death responsible for disrupted vasculariza-
tion, extensive hemorrhages and, consequently, embryonic
lethality. Reduced viability and defective tubulogenesis
demonstrated in FLVCR1a-silenced HMECs strongly sup-
ports this conclusion.
We identified the mechanism of EC death induced by
endogenously synthetized heme accumulation as paraptosis,
a specific type of PCD characterized by extensive cyto-
plasmic vacuolation that begins with a progressive swelling
of ER and mitochondria [16, 17, 28]. The term “paraptosis”
was first introduced by Sperandio et al. [16] to describe a
form of PCD morphologically and biochemically distinct
from apoptosis. Indeed, paraptosis does not involve the
activation of caspases nor the classical morphological
changes found in cells undergoing apoptosis [16, 17].
Similarly to other PCDs, paraptosis is known to require de
novo protein synthesis. Consistently, inhibition of protein
synthesis by CHX is able to rescue heme-induced cyto-
plasmic vacuolation in ALA treated FLVCR1a-silenced
HMECs. The molecular mechanisms through which heme
triggers paraptosis in ECs is unclear. ER stress and accu-
mulation of unfolded proteins are known to be involved in
paraptosis [19, 21, 22, 29, 30]. Notably, several indications
of ER stress were found in both Flvcr1a null embryonic
ECs and FLVCR1a-silenced human ECs, suggesting that
ER stress might contribute to the cell death process. In
particular, dilation of the ER-lumen and increased expres-
sion of ER stress markers were observed in ECs without
FLVCR1a both in vivo and in vitro. Moreover, ALA
treatment was shown to increase the expression of GRP78/
BIP protein in human ECs, further correlating heme accu-
mulation and ER stress. These data taken together strongly
suggest that heme-induced vacuolation can be preceded by
induction of ER stress. Consistently, heme excess has been
shown to inhibit the proteasome leading to accumulation of
misfolded proteins and ER stress [31]. Furthermore, protein
aggregation has been recently reported as a cellular
response to oxidative stress induced by heme [32]. Never-
theless, we cannot exclude a contribution of intracellular
ROS to the mechanism of heme-induced EC death. Heme is
known to promote the formation of ROS as previously
demonstrated in other models of Flvcr1a deficiency [10,
12]. Consistently, FLVCR1a-silenced ECs displayed
enhanced ROS production. Although we were not able to
measure a significant increase of ROS in CD31+ cells from
Flvcr1a eKO embryos, we think that a mild production of
ROS in Flvcr1a null ECs might sensitize the cells to
paraptosis as previously reported in other systems [19–21,
33]. Finally, the swollen morphology of ER and
mitochondria observed in Flvcr1a null ECs and FLVCR1a-
silenced human ECs indicates an imbalance in ions home-
ostasis (e.g., Ca2+ and K+). Accordingly, alterations in
ions exchange between ER and mitochondria are involved
in paraptosis [21, 34, 35].
Interestingly, some natural and synthetic compounds used
as anticancer agents, exert a pro-paraptotic effect, which is
applied as an alternative way to kill cancer cells resistant to
apoptosis [29, 30, 36, 37]. As evasion of cell death is one of
the hallmarks of tumorigenesis, the elucidation of the
mechanisms promoting non-canonical types of cell death can
provide novel therapeutic options [36]. In this context, the
finding that intracellular heme accumulation promotes para-
ptosis opens new perspectives based on the manipulation of
intracellular heme pool for reducing tumor growth. In parti-
cular, angiogenesis is an important rate-limiting step in tumor
growth and anti-angiogenesis therapy represents a valuable
opportunity for cancer treatment [38]. Our data suggest that
heme-promoted paraptosis might be exploited as a way for
reducing tumor angiogenesis. We can speculate that agents
aimed at increasing cytosolic heme by promoting heme
synthesis, blocking heme export and/or heme catabolism
might have anti-angiogenic effects [39]. These drugs could be
used in combination with other drugs to improve antitumor
efficacy by killing apoptosis-resistant cells.
Cell death through paraptosis has been reported also in
other pathological conditions. For instance, paraptosis has
been described in neural development and neurodegenera-
tion (e.g., amyotrophic lateral sclerosis and Huntington’s
disease), in the ischemic damage and in the context of retina
pathophysiology [36]. Interestingly, Flvcr1 gene is mutated
in posterior column ataxia with retinitis pigmentosa and
hereditary sensory and autonomic neuropathy type 2, both
characterized by degeneration of specific neuronal cell types
[14, 40, 41]. We hypothesize that impaired FLVCR1
function in these patients might promote paraptosis of
specific cell types.
In conclusion, our data unravel the critical role of the
physiologic regulation of the intracellular heme pool for the
maintenance of ECs homeostasis and their angiogenic
functions. We speculate that acting on the endothelial heme
pool might provide novel therapeutic options for controlling
neo-angiogenesis in cancer and other pathologies char-
acterized by enhanced/aberrant vascularization.
Materials and methods
Generation and analysis of Flvcr1a-conditional
mutant mice
Endothelial-specific conditional Flvcr1a knockout mice
were generated by crossing Flvcr1afl/+; Tie2-Cre male
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mice with Flvcr1afl/fl female mice [10] to generate EC-
specific deletion of Flvcr1a gene (Flvcr1afl/fl; Tie2-Cre).
Upon Cre-mediated recombination, excision of the first
exon would fully inactivate the gene in ECs, creating a null
Flvcr1a allele (Flvcr1a null). Mice were genotyped by PCR
analyses using DNA from yolk sacs or tail biopsies. To
detect the Cre allele, primers Cre-Fw (5ʹ-GGA-
CATGTTCAGGGATCGCCAGGCG-3ʹ) and Cre-Rev (5ʹ-
GCATAACCAGTGAAACAGCATTGCT-3ʹ) were used.
To detect the Flvcr1a null allele, primers ILox-Fw (5ʹ-
TCTAAGGCCCAGTAGGACCC-3ʹ) and IILox-Rev (5ʹ-
AGAGGGCAACCTCGGTGTCC-3ʹ) were used, given a
320-bp fragment. To analyze the LoxP sites on Flvcr1 gene,
primers ILox-Fw (5ʹ-TCTAAGGCCCAGTAGGACCC-3ʹ)
and ILox-Rev (5ʹ-GAAAGCATTTCCGTCCGCCC-3ʹ)
were used, given a 280-bp band for the floxed allele and a
242-bp band for the wild-type allele (Fig. 2a). Embryos
were obtained from timed pregnant females with the
morning of vaginal plug considered E0.5. All experiments
were approved by the animal studies committee of the
University of Torino (Italy).
Whole-mount immunostaining
Whole-mount staining was performed as previously
described [42], using anti-mouse CD31 (Pecam-1) mono-
clonal antibody (BD Biosciences, Franklin Lakes, NJ,
USA). 3,3′-diaminobenzidine (DAB)/hydrogen peroxide
was used for visualization.
CD31+ cells isolation from mouse embryo
E13.5–14.5 embryos were isolated from Tie2-Cre transgenic
mice and minced into 1–2mm fragments with a scalpel. After
rinsing in phosphate-buffered saline (PBS), the tissue pieces
were incubated for 45min at 37 °C in 10ml of pre-warmed
PBS with collagenase (5 mg/ml, Collagenase Type II, Wor-
thington, CLS-2) with shaking until a single-cell suspension
was obtained. During this incubation, the cells were dis-
sociated at 10-min intervals by pipetting. To stop the col-
lagenase activity, Dulbecco’s modified Eagle’s medium
(Invitrogen) containing 10% fetal bovine serum (FBS; Invi-
trogen) was added to the cell suspension, gently pelleted and
rinsed with PBS. The cells in PBS were then filtered through a
cell strainer (40mm mesh, BD Falcon). After centrifugation,
cells were re-suspended in 1ml NH4Cl 154mM, overlaid onto
5ml of FBS and centrifuged. If red blood cells were not fully
removed, this step was repeated. Cells were washed and re-
suspended in PBS. Then, embryonic cells were magnetically
labeled with MicroBeads conjugated to monoclonal
anti‑mouse CD31 antibody (Miltenyi Biotec) and loaded onto
a MACS® Column, which was placed in the magnetic field of
a MACS Separator. After removing the column from the
magnetic field, the magnetically retained CD31+ cells were
eluted as the positively selected cell fraction.
RNA extraction and real-time PCR analysis
Total RNA was extracted from tissue and cell samples using
PureLink® RNA Mini Kit (ThermoFisher Scientific). For
quantitative real-time polymerase chain reaction (qRT-PCR),
0.5–1 μg total RNA was transcribed into complementary
DNA by M-MLV reverse transcriptase (Invitrogen) and
random primers (Invitrogen). qRT-PCR was performed on a
7900HT Fast Real-Time PCR System (Applied Biosystems,
Monza, Italy). Primers and probes were designed using the
Universal ProbeLibrary Assay Design Center software
(www. lifescience.roche.com). For FLVCR1a, specific pri-
mers and the probe were designed using Primer Express
Software Version 3.0 (Applied Biosystems). Transcript
abundance, normalized to 18s mRNA expression (for mouse
tissues) or to beta-actin mRNA expression (for human cells),
is expressed as a fold increase over a calibrator sample.
Western blotting
For western blot analysis, 20 μg of CD31+ cells protein
extracts were loaded on 15% sodium dodecyl sulfate-
polyacrylamide gels and analyzed by western blotting as
previously described [43]. Cleaved caspase-3 (Asp175)
antibody (Cell Signaling) was used to recognize the acti-
vated caspase-3 resulting from cleavage adjacent to Asp175
(17–19 kDa). Full-length caspase-3 (Cell Signaling) anti-
body was used to detect the full-length protein (35 kDa).
Rabbit polyclonal antibody against LC3 (TA301542, Ori-
gene) was used to detect conversion of LC3-I (cytosolic) to
LC3-II (autophagic vacuole membrane bound). Purified
mouse anti-Grp78/Bip (610979, BD Transduction Labora-
tories) was used to detect the protein expression in HMECs.
Cell culture
HUVECs were propagated in M199 medium (Invitrogen)
with 20% FBS (Invitrogen), 100 U/ml penicillin, 100 μg/ml
streptomycin, 20 U/ml Heparin sodium salt from porcine
intestinal mucosa (Sigma), 10 ng/ml recombinant human
Fibroblast Growth Factor (FGF)-basic (PeproTech).
HUVECs were used up to passages 6. Human adult dermal
microvascular ECs were purchased by Lonza and propa-
gated in EndoGRO MV-VEGF medium (Millipore, Merck,
Italy) and used up to passages 12. Cells were maintained at
37 °C under a 5% CO2 atmosphere. To induce endogenous
heme biosynthesis, 5-aminolevulinic acid hydrochloride
(A3785, Sigma) was added to the cell medium. To inhibit
protein synthesis, CHX (5 μg/ml, Sigma) was added to the
cell medium.
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FLVCR1a silencing
A set of five pLKO.1 HIV-based lentiviral vectors targeting
human FLVCR1 gene were purchased (RHS4533-
NM_014053, Dharmacon). A shRNA against the first exon
of human FLVCR1 gene was used to specifically down-
regulate FLVCR1a expression. The lentiviruses pLKO.1-scr
(expressing a “scramble” shRNA as control) and pLKO.1-1a
(expressing the shRNA specific for FLVCR1a) were pro-
duced in HEK293FT cells. HMEC and HUVEC cells were
infected with the lentiviruses in the presence of Sequa-
brene. Following lentiviral infection, cells were selected
with 0.02 μg/ml puromycin.
Measurement of heme concentration
Intracellular heme concentration was measured using a
fluorescence assay, as previously reported [44]. Briefly,
HMEC and HUVEC cells or CD31+/- embryonic cells
were collected and 2M oxalic acid was added to them.
Samples were heated at 95 °C for 30 min leading to iron
removal from heme. Fluorescence (wavelengths: excitation
400 nm – emission 662 nm) of the resultant protoporphyrin
was assessed on a Glomax Multi Detection System (Pro-
mega Corporation). The endogenous protoporphyrin con-
tent (measured in parallel unheated samples in oxalic acid)
was subtracted. Data were normalized to total protein con-
centration in each sample.
Measurement of intracellular ROS content in vitro
Accumulation of ROS in HMEC and HUVEC cells was
assessed using the oxidant-sensitive fluorescent dye 29,79-
dichlorodihydrofluoroscein diacetate (H2DCFDA, Ther-
moFisher Scientific). Cells were incubated with 5 mM
H2DCFDA in cell medium for 30 min at 37 °C under 5%
CO2 atmosphere. Then, cells were washed twice with PBS
and lysed in TBS 1× 1% Triton. A quantity of lysate cor-
respondent to 10 μg protein was analyzed. Fluorescence was
recorded at excitation and emission wavelengths of 485 and
530, respectively, on a Glomax Multi Detection System
(Promega Corporation). Background fluorescence of cells
untreated with H2DCFDA was subtracted from the total
fluorescence. Results are expressed as arbitrary fluorescence
unit.
MTT assay and Annexin V affinity assay
In all, 5×103 HMEC or HUVEC cells were plated on 96
multiwells, and every 24 h cell growth was evaluated by
MTT assay (Roche) according to the manufacturer’s
instructions. For Annexin V affinity assay, 5×105 cells
were collected, washed in PBS and labeled with Annexin V
(BD Biosciences) for 20 min. Then, 2 μl of propidium
iodide (1 mg/ml) (Sigma-Aldrich) were added. Annexin V
emission was detected in the green channel (525 nm) and
propidium iodide in the red channel (575 nm) on a FACS-
Calibur (BD Biosciences) using Cell Quest Pro Software
(BD Biosciences).
Tubulogenesis assay
In vitro formation of capillary-like structures was studied on
growth factor-reduced Matrigel (BD Biosciences) in 24-
well plates. Cells (3.5× 104] cells per well) were seeded
onto Matrigel-coating in EndoGRO MV-VEGF (Millipore).
Cell organization onto Matrigel was observed with a Nikon
Eclipse Ti E microscope using a Nikon Plan 10X/0,10
objective and cells were kept at 37 °C and 5% CO2 during
the experiment. Images were acquired after 8 h. At least
three independent experiments were done for each experi-
mental condition. ImageJ’s Angiogenesis Analyzer was
used to analyze: master segments, master junctions, isolated
segments, total length, total master segments length and
nodes.
Micro-computed tomography
Micro-CT analysis was performed on E13.5 mouse embryos
using a Bruker Skyscan 1172 micro-CT. Embryos were
fixed in formalin and then stained for 6 days with a soft
tissue contrast agent (phosphotungstic acid 2.5% dissolved
in water). Acquisition were performed at 80 kV using a 0.5
mm Al filter at a resolution of 3 µm, 0.4° of rotation step,
360° scan, 4× frame averaging.
Electron microscopy
The transmission electron micrographs were obtained at the
Advanced Light and Electron Microscopy BioImaging
Center (ALEMBIC), San Raffaele, Milano, Italy.
Statistics
Results were expressed as mean ± SEM. Statistical analyses
were performed using one-way or two-way analysis of
variance or Student’s t-test. A p-value of <0.05 was con-
sidered significant.
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